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Neglected tropical 
disease targets must 
include morbidity
The Royal Society of Tropical 
Medicine and Hygiene is holding a 
1-day meeting in London, UK, on 
Sept 25, 2015, to discuss “The disease 
elimination agenda: the role of science, 
policy and advocacy”.1 Important 
meetings such as this are a welcome 
forum at which to discuss progress and 
challenges and to reﬂ ect on important 
milestones, particularly with regard 
to neglected tropical diseases (NTDs). 
Such NTD milestones include the 
London declaration2 and the WHO 
roadmap.3 However, the success 
of these elimination initiatives is 
contingent on inclusive programming 
and on addressing the problem in its 
entirety.
Most of the targets for elimination 
focus on interrupting transmission 
and infection cycles, yet many of 
the NTDs cause severe morbidity 
including disabling lymphoedema, 
massive hydrocele, disﬁ gurement, and 
blindness.4 Despite the huge burden of 
morbidities, there are no clear targets 
towards their elimination, and, with 
the exception of trachoma, there are 
no morbidity indictors to measure 
the success of elimination.5 A more 
inclusive approach to addressing 
morbidity in the elimination of NTDs 
should focus on the following points.
First, elimination targets should 
clearly include indicators related to 
morbidity. Such indicators should 
go beyond measuring access to 
care and should bind success to 
the extent of morbidity alleviation. 
WHO’s trachoma elimination target 
of a prevalence of active trachoma 
of less than 5% among children 
aged 1–9 years and a prevalence of 
trachoma trichiasis of less than one 
case per 1000 population5 successfully 
combines both prevention of new 
infections and reduction of morbidity, 
and should be replicated across the 
diﬀ erent diseases.
Second, resources should be 
clearly committed to the morbidity 
management aspect of these NTDs. 
Funding such as the USAID’s support of 
Helen Keller International’s Morbidity 
Management and Disability Prevention 
for Blinding Trachoma and Lymphatic 
Filariasis Project is welcome.6 Given the 
scale of the problem, more resources 
to address the morbidity challenge 
are required. As resources are directed 
towards preventing new infection, 
equally resources should also be 
targeted to improving the quality of 
life of the people suﬀ ering from the 
consequences of the diseases. 
Third, operational research into 
optimising the delivery of morbidity 
management services is also important. 
One of the challenges of scaling up such 
services is a dearth of evidence on how 
to integrate them into the existing 
health systems and ongoing NTD 
programmes. Operational research 
focusing on integration of services, 
surveillance, and barriers to the existing 
services will be important.
To achieve the challenges of 
elimination, morbidity management 
is essential, not optional. Strong 
advocacy and awareness-raising for 
donors is important, but the change 
should start from within by including 
morbidity targets in some of the NTD 
elimination targets. 
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